Lotus Pharmaceutical Co., Ltd.

TWSE:1795 株式レポート

時価総額：NT$74.7b

Lotus Pharmaceutical マネジメント

マネジメント 基準チェック /14

Lotus Pharmaceuticalの CEO はPetar Vazharovで、 Jan2018年に任命され、 の在任期間は 6.83年です。 は、会社の株式の0.38%を直接所有しており、その価値はNT$ 281.50M 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と1.4年です。

主要情報

Petar Vazharov

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間6.8yrs
CEOの所有権0.4%
経営陣の平均在職期間3.3yrs
取締役会の平均在任期間1.4yrs

経営陣の近況

Recent updates

Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Nov 16
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Nov 14
Lotus Pharmaceutical's (TWSE:1795) Earnings Are Weaker Than They Seem

Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Oct 23
Here's Why Lotus Pharmaceutical (TWSE:1795) Has A Meaningful Debt Burden

Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Aug 14
Lotus Pharmaceutical Co., Ltd. Just Missed Revenue By 5.2%: Here's What Analysts Think Will Happen Next

Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Jul 18
Investors Continue Waiting On Sidelines For Lotus Pharmaceutical Co., Ltd. (TWSE:1795)

Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Apr 24
Is Lotus Pharmaceutical (TWSE:1795) Using Too Much Debt?

Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Apr 09
Benign Growth For Lotus Pharmaceutical Co., Ltd. (TWSE:1795) Underpins Its Share Price

Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

Mar 22
Lotus Pharmaceutical's (TWSE:1795) Solid Profits Have Weak Fundamentals

These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Apr 04
These 4 Measures Indicate That Lotus Pharmaceutical (TPE:1795) Is Using Debt Extensively

Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Mar 09
Lotus Pharmaceutical Co., Ltd.'s (TPE:1795) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Feb 11
Did You Miss Lotus Pharmaceutical's (TPE:1795) 64% Share Price Gain?

Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Jan 21
Should You Use Lotus Pharmaceutical's (TPE:1795) Statutory Earnings To Analyse It?

Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

Dec 31
Is Lotus Pharmaceutical (TPE:1795) Using Too Much Debt?

I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Dec 10
I Ran A Stock Scan For Earnings Growth And Lotus Pharmaceutical (TPE:1795) Passed With Ease

Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

Nov 19
Lotus Pharmaceutical Co., Ltd. Just Missed EPS By 6.5%: Here's What Analysts Think Will Happen Next

CEO報酬分析

Lotus Pharmaceutical の収益と比較して、Petar Vazharov の報酬はどのように変化したか？
日付総報酬給与会社業績
Sep 30 2024n/an/a

NT$4b

Jun 30 2024n/an/a

NT$4b

Mar 31 2024n/an/a

NT$4b

Dec 31 2023n/an/a

NT$4b

Sep 30 2023n/an/a

NT$4b

Jun 30 2023n/an/a

NT$5b

Mar 31 2023n/an/a

NT$4b

Dec 31 2022n/an/a

NT$3b

Sep 30 2022n/an/a

NT$3b

Jun 30 2022n/an/a

NT$1b

Mar 31 2022n/an/a

NT$1b

Dec 31 2021NT$35mNT$28m

NT$1b

Sep 30 2021n/an/a

NT$1b

Jun 30 2021n/an/a

NT$1b

Mar 31 2021n/an/a

NT$1b

Dec 31 2020NT$18mNT$14m

NT$1b

Sep 30 2020n/an/a

NT$848m

Jun 30 2020n/an/a

NT$769m

Mar 31 2020n/an/a

NT$519m

Dec 31 2019NT$13mNT$7m

NT$663m

報酬と市場: Petarの 総報酬 がTW市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Petarの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Petar Vazharov

6.8yrs

在職期間

NT$34,721,000

報酬

Mr. Petar Antonov Vazharov serves as a Director at Alvogen Korea Co. Ltd. Since March 31, 2021. He is an Executive Vice President of the Asia Pacific Region of Alvogen Group.He is General Manager of Alvog...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Petar Vazharov
CEO & Director6.8yrsNT$34.72m0.38%
NT$ 281.5m
Eeling Chan
Chief Financial Officer8yrsNT$5.19m0.010%
NT$ 7.5m
Vamsi Kosaraju
Chief Operations Officerno dataデータなしデータなし
Gwen Hsieh
Chief Information Officer3.3yrsデータなし0.0084%
NT$ 6.3m
Yu-Ying Yang
Associate Director of Co-Operate Communicationno dataデータなしデータなし
Boon Tan
Deputy General Managerno dataデータなし0.0077%
NT$ 5.8m
Edin Buljubasic
Vice Presidentno dataデータなし0.057%
NT$ 42.2m
Yingming Yue
Vice Presidentno dataデータなし0.011%
NT$ 8.4m
Valerie Lau
Chief Commercial Officer-APACless than a yearデータなしデータなし
Manish Chawla
Vice President of Research and Developmentno dataデータなし0.026%
NT$ 19.7m

3.3yrs

平均在職期間

経験豊富な経営陣: 1795の経営陣は 経験豊富 であると考えられます ( 3.3年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
Petar Vazharov
CEO & Director10.2yrsNT$34.72m0.38%
NT$ 281.5m
Vilhelm Wessman
Chairman9.6yrsNT$959.00kデータなし
Karl Alexius Tiger Karlsson
Independent Director1.4yrsデータなしデータなし
Oranee Tangphao-Daniels
Director2.4yrsデータなしデータなし
Arni Hardarson
Representative Directorless than a yearNT$959.00kデータなし
Yves Hermes
Director2.4yrsデータなしデータなし
Chuan-Fen Wang
Independent Dierctor1.4yrsデータなしデータなし
Nat Ativitavas
Representative Director1.2yrsデータなしデータなし
Krisana Winitthumkul
Director2yrsデータなしデータなし
Ivy Yang
Independent Directorless than a yearデータなしデータなし
Thariswan Tiensawat
Representative Directorless than a yearデータなしデータなし

1.4yrs

平均在職期間

55yo

平均年齢

経験豊富なボード: 1795の 取締役会 は 経験豊富 ではない ( 1.4年の平均在任期間) ため、新しい取締役会が必要であると考えられます。